1 / 13

A European biopharmaceutical group specialised in therapeutic proteins

A European biopharmaceutical group specialised in therapeutic proteins. Company Profile.

lot
Télécharger la présentation

A European biopharmaceutical group specialised in therapeutic proteins

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A European biopharmaceutical group specialised in therapeutic proteins

  2. Company Profile • LFB is a biopharmaceutical group which develops, manufactures and markets medicinal products for the treatment of serious and often rare diseases in major therapeutic areas: immunology, haemostasis and intensive care. • Number one in France and fifth in the world for plasma-derived medicinal products, the LFB group is also one of the leading European companies for the development and production of proteins and innovative treatments derived from biotechnologies. • Relying on its sustained research effort, the LFB group is implementing a growth strategy to expand its activities to international markets.

  3. In France, the LFB Group is a public health player • Specific missions precised in national law • Loi HPST, article 77 • Consists in : • giving priority to meeting the country’s demand with products derived from French plasma • …going with LFB’s exclusive fractionation rights on the plasma from voluntary donations collected on the French territory Engagement particulier dans les maladies rares • acknowledgement of LFB’s strong implication in the field of rare diseases

  4. Key dates

  5. 2012 key figures • € 465,7 million turnover: 7,7 % growth • 3rdpharmaceutical company serving hospitals in France • 5th pharmaceutical company worldwide specialised in plasma-derived medicinal product • 1 887 employees

  6. GROUP ORGANIZATION CHART LFB S.A. EUROPLASMA Holding AT (Austria) Europlasma GmbH (Austria) LFB HEMODERIVADOS E BIOTECNOLOGIA LTDA (Brazil) Europlasma Sro (Czech Republic) LFB GmbH (Germany) LFB BIOMEDICAMENTS S.A. (France) LFB TECNOLOGIA LTDA (Brazil) LFB BIOPHARMACEUTICALS LTD (Great Britain) LFB MIDDLE EAST S.A. (Belgium) rEVO BIOLOGICS. (United States) LFB BIOTECHNOLOGIES S.A.S. (France) LFB BIOMANUFACTURING S.A.S. (France) CELLforCURE S.A.S (France) Minority stake

  7. Medicinal products of LFB for serious and in many cases rare diseases

  8. A strong international development for the LFB Group • 5thplayerworldwide in the field of plasma-derivedmedicinalproducts • International activities turnover increase by 60% in 2012 • Exportation of LFB products (immunoglobulins in Brazil, Turkey; launch of Willebrand factor in Europe; massive albumin sales in Brazil, Middle East and Asia). • Production for third parties • Brazil, Morocco, Belgium • Technologytransfer

  9. Our mission : develop innovative therapies • Plasma-derived medicinal products : for serious and often rare diseases • Therapeutic proteins derived from biotechnology : to meet uncovered needs in France and worldwide

  10. Corporate Social Responsibility

  11. Fundamental principles and strong values • Putting patients' safety at the heart of corporate decisions. • Developing programmes for rare diseases. • Building ethical relationships with stakeholders, healthcare professionals, employees and partners, and developing projects with associations whose role it is to improve the quality of life of patients and their families. • Implementing proactive policies aimed at controlling energy and water consumption and waste generation from our operating activities to protect the environment and non-renewable resources.

  12. Our special commitment in the field of rare diseases • > 60% of LFB products are indicated in rare diseases • The LFB Groups’ R&D projects include major steps for rare diseases • Development of new indications for existing products • New medicinal products • LFB supports major players in the rare diseases field • Orphanet • Alliance Maladies Rares (France) • CEREDIH (France) • EURORDIS (Europe) • WFH, IPOPI

  13. Partnerships oriented towards patients • Improving the lives of patients • Sponsoring for patients groups and associations • Help improve long hospital stays, especially for young patients • Le Rire Médecin, IRIS • Help deliver adapted information to young patients about their diseases • ADAAT / Sparadrap • Improve knowledge of rare diseases • Alliance Maladies Rares • AFH, ADAAT, IRIS, Eurordis, AFNP, AF3M …

More Related